Recognition and management of organ-specific toxicities associated with enfortumab vedotin plus pembrolizumab and erdafitinib in locally advanced or metastatic urothelial carcinoma
Cancer Treatment Reviews · 2026-12 · 151 · 103233
DOI: 10.1016/j.ctrv.2026.103233 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2026-12. Verfasst von María José Juan Fita und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Fundación Instituto Valenciano de Oncología, Profesor Beltrán Báguena 8, Valencia, 46009, Spain. Electronic address: …. Die Arbeit nennt 52 Literaturangaben. Gefördert von: Astellas Pharma Inc, Johnson and Johnson Pharmaceuticals.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Fundación Instituto Valenciano de Oncología, Profesor Beltrán Báguena 8, Valencia, 46009, Spain. Electronic address: mjjuan@fivo.org.
- Department of Medical Oncology, Hospital Clínico Universitario de Santiago, Rúa da Choupana s/n, 15706 Santiago de Compostela, A Coruña, Spain.
- Department of Neurology, Fundación Instituto Valenciano de Oncología, Department of Medicine, University of Valencia, Profesor Beltrán Báguena 8, Valencia, 46009, Spain. Electronic address: lbataller@fivo.org.
- Department of Medical Oncology, Hospital Universitario 12 de Octubre, Avda. de Córdoba s/n, Madrid, 28041, Spain.
- Department of Ophthalmology, Hospital Clínico San Carlos, San Carlos Health Research Institute (IdISSC), Profesor Martín Lagos s/n, Madrid, 28040, Spain.
- Department of Medical Oncology, Complejo Hospitalario Universitario Insular-Materno Infantil, Avenida Marítima del Sur, s/n, 35016 Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.
Förderung
- Astellas Pharma Inc
- Johnson and Johnson Pharmaceuticals
Zitieren
APA
Juan Fita, M. J., Anido, U., Bataller, L., de Velasco, G., Fernández-Vigo, J. I., Gómez de Liaño, A., Sanmartín Jiménez, O., & Pinto, Á. (2026). Recognition and management of organ-specific toxicities associated with enfortumab vedotin plus pembrolizumab and erdafitinib in locally advanced or metastatic urothelial carcinoma. Cancer Treatment Reviews, 151, 103233. https://doi.org/10.1016/j.ctrv.2026.103233
Vancouver
Juan Fita MJ, Anido U, Bataller L, de Velasco G, Fernández-Vigo JI, Gómez de Liaño A, et al. Recognition and management of organ-specific toxicities associated with enfortumab vedotin plus pembrolizumab and erdafitinib in locally advanced or metastatic urothelial carcinoma. Cancer Treatment Reviews. 2026;151:103233. doi:10.1016/j.ctrv.2026.103233
BibTeX
@article{JuanFita2026,
author = {Juan Fita, María José and Anido, Urbano and Bataller, Luis and de Velasco, Guillermo and Fernández-Vigo, José Ignacio and Gómez de Liaño, Alfonso and Sanmartín Jiménez, Onofre and Pinto, Álvaro},
title = {Recognition and management of organ-specific toxicities associated with enfortumab vedotin plus pembrolizumab and erdafitinib in locally advanced or metastatic urothelial carcinoma},
journal = {Cancer Treatment Reviews},
year = {2026},
volume = {151},
pages = {103233},
doi = {10.1016/j.ctrv.2026.103233}
}
EUVIMED